These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2108908)

  • 1. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
    Hoogerbrugge-vd Linden N; de Rooy FW; Jansen H; van Blankenstein M
    Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in biliary lipid output after interruption of pravastatin treatment in humans.
    Hillebrant CG; Eriksson M; Nyberg B; Einarsson K
    Eur J Clin Invest; 1996 Dec; 26(12):1160-5. PubMed ID: 9013093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
    Koide K; Hayashi K; Horiuchi I; Kajiyama G
    Biochim Biophys Acta; 1989 Sep; 1005(1):65-71. PubMed ID: 2505850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
    Tazuma S; Takizawa I; Kunita T; Mizuno T; Watanabe T; Teramen K; Horikawa K; Ochi H; Yamashita Y; Aihara N
    Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation.
    Muraca M; Baggio G; Miconi L; Vilei MT; Martini S; Gabelli C; Belluco C; Lise M; Crepaldi G
    Eur J Clin Invest; 1991 Apr; 21(2):204-8. PubMed ID: 1905632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia.
    Horiuchi I; Ohya T; Tazuma S; Mizuno T; Takizawa I; Kajiyama G
    Metabolism; 1991 Mar; 40(3):226-30. PubMed ID: 1900342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of withdrawal of pravastatin on biliary lipid composition in humans.
    Muraca M; Baggio G; Vilei MT; Martini S; Cianci V; Crepaldi G
    Atherosclerosis; 1996 Jun; 123(1-2):133-7. PubMed ID: 8782844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.
    Hoogerbrugge N; Mol MJ; Van Dormaal JJ; Rustemeijer C; Muls E; Stalenhoef AF; Birkenhäger JC
    J Intern Med; 1990 Sep; 228(3):261-6. PubMed ID: 2119419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
    Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
    Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
    J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
    Kallien G; Lange K; Stange EF; Scheibner J
    Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
    Smit JW; Van Erpecum KJ; Portincasa P; Renooij W; Erkelens DW; Van Berge-Henegouwen GP
    Gut; 1995 Nov; 37(5):654-9. PubMed ID: 8549941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
    Wiklund O; Angelin B; Fager G; Eriksson M; Olofsson SO; Berglund L; Lindén T; Sjöberg A; Bondjers G
    J Intern Med; 1990 Sep; 228(3):241-7. PubMed ID: 2119417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
    Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
    Eur J Clin Invest; 1998 Apr; 28(4):324-8. PubMed ID: 9615912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?
    Smit JW; Van Erpecum KJ; Gadella MM; Van de Heyning BJ; Van Berge-Henegouwen GP
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):197-200. PubMed ID: 8724016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
    Miettinen TA
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S19-21. PubMed ID: 1904356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.